A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Belimumab (Primary) ; Rituximab
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLISS-BELIEVE
- Sponsors GlaxoSmithKline
- 10 Apr 2018 Planned End Date changed from 2 Jun 2021 to 9 Jun 2021.
- 10 Apr 2018 Planned primary completion date changed from 27 Aug 2020 to 11 Jun 2020.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.